SPORE in Prostate Cancer

前列腺癌中的孢子

基本信息

批准号：
10478810
负责人：
Sarki A. Abdulkadir
金额：
$ 175.93万
依托单位：
NORTHWESTERN UNIVERSITY AT CHICAGO
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-18 至 2026-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10478810
关键词：
Advocacy Advocate Aggressive course American Antibody Therapy Antitumor Response Basic Science Bioinformatics Biology Biometry Biopsy Specimen Blood specimen Cancer Etiology Cancer Patient Catchment Area Chicago Clinical Clinical Sciences Clinical Trials Collaborations Combined Modality Therapy Comprehensive Cancer Center Core Facility DNA Damage Development Diagnosis Disease FDA approved Family member Focus Groups Friends Funding Genetic Transcription Health Health system Human Immune system Immunotherapy Infrastructure Innovative Therapy Institution Leadership MHC Class I Genes Malignant neoplasm of prostate Measurable Measures Mediating Metastatic Prostate Cancer Myelogenous National Cancer Institute Oncogenic PTEN gene Pathologist Pathway interactions Patient Care Patient-Focused Outcomes Patients Pharmacologic Substance Phase I Clinical Trials Phosphorylation Pre-Clinical Model Prostate specific antigen measurement Quality of life Regulation Research Research Personnel Research Project Grants Resistance STING agonists Scientist Signal Transduction Source Talents Testing Therapeutic Tissues Translating Translational Research Translations Treatment Efficacy Tumor-infiltrating immune cells Universities Visceral Work Yang anticancer research base bone c-myc Genes cancer genetics career castration resistant prostate cancer cohort design experience experimental study humanized monoclonal antibodies immune checkpoint blockade improved improved outcome inhibitor innovation investigator-initiated trial meetings member men mortality mouse model new technology novel novel strategies novel therapeutics patient population preclinical study programmed cell death protein 1 programs prostate cancer model recruit safety study success targeted treatment tumor tumor microenvironment tumor-immune system interactions

项目摘要

OVERALL: ABSTRACT This application is a request for renewal funding of the SPORE in Prostate Cancer P50 CA180995 at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in collaboration with the University of Chicago Comprehensive Cancer Center and NorthShore University HealthSystem, an affiliate of the University of Chicago. The SPORE first received support from the National Cancer Institute in 2001; a renewal application was funded in 2009. In 2015, we were the recipients of a new SPORE and we are now requesting continued funding for this program. Our SPORE unites basic scientists, clinicians, pathologists, biostatisticians, bioinformaticists and advocates from our academic institutions, all of whom are dedicated to advancing translational prostate cancer research. In this application we propose three highly translational and innovative research projects that have both basic science and clinical science co-leadership: Project 1: Targeting the MYC Pathway in Prostate Cancer (Abdulkadir, Hussain); Project 2: Re-directing the sensitivity of metastatic castration-resistant prostate cancer to immunotherapy (Wu, Sosman, Morgans); Project 3: STING Activation to Overcome Resistance to Immune Checkpoint Blockade in PTEN-deficient Prostate Cancer (Patnaik, Gajewski, Stadler). Three core facilities support the proposed research projects: Administrative, Leadership and Advocacy (Abdulkadir, Hussain, Stadler); Biostatistics/Bioinformatics (Kocherginsky, Zhao) and Biospecimen (Yang). Internal and External Advisory Boards provide a source of scientific input to members of the SPORE team on a biannual and yearly basis, respectively. Our Advocacy Group are well established in the SPORE arena and make a valued contribution to our success. The SPORE includes Developmental Research and Career Enhancement Programs, both of which provide a source of innovation and new discoveries. All together, we anticipate that the results obtained from our research endeavors will have a significant impact on the health of patients diagnosed with prostate cancer.

总体：摘要本申请是罗伯特癌症中心 SPORE 前列腺癌 P50 CA180995 续期资助的请求西北大学 H. Lurie 综合癌症中心与芝加哥大学合作综合癌症中心和北岸大学健康系统（北岸大学附属机构）芝加哥。 SPORE于2001年首次获得美国国家癌症研究所的支持；续签申请于 2009 年获得资助。2015 年，我们是新 SPORE 的接收者，现在我们请求继续该计划的资金。我们的 SPORE 将基础科学家、临床医生、病理学家、生物统计学家、来自我们学术机构的生物信息学家和倡导者，他们都致力于推进转化前列腺癌研究。在此应用中，我们提出了三个高度转化和创新的基础科学和临床科学共同领导的研究项目：项目 1：针对 MYC 前列腺癌途径（Abdulkadir，Hussain）；项目 2：重新引导转移的敏感性去势抵抗性前列腺癌的免疫治疗（Wu、Sosman、Morgans）；项目 3：STING 激活克服 PTEN 缺陷型前列腺癌对免疫检查点阻断的耐药性（Patnaik、Gajewski、斯塔德勒）。三个核心设施支持拟议的研究项目：行政、领导和宣传（阿卜杜勒卡迪尔、侯赛因、斯塔德勒）；生物统计学/生物信息学（Kocherginsky，Zhao）和生物样本（Yang）。内部和外部顾问委员会为 SPORE 团队成员提供科学投入的来源分别为每两年一次和每年一次。我们的倡导小组在 SPORE 领域颇有建树，并且为我们的成功做出宝贵贡献。 SPORE 包括发展研究和职业增强计划，两者都提供创新和新发现的源泉。大家一起，我们预计我们的研究工作所获得的结果将对人们的健康产生重大影响诊断患有前列腺癌的患者。